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Abstract: We describe in this review the different types of injuries caused to the biliary tree
after liver transplantation. Furthermore, we explain underlying mechanisms and why oxygenated
perfusion concepts could not only protect livers, but also repair high-risk grafts to prevent
severe biliary complications and graft loss. Accordingly, we summarize experimental studies
and clinical applications of machine liver perfusion with a focus on biliary complications after
liver transplantation. Key points: (1) Acute inflammation with subsequent chronic ongoing liver
inflammation and injury are the main triggers for cholangiocyte injury and biliary tree transformation,
including non-anastomotic strictures; (2) Hypothermic oxygenated perfusion (HOPE) protects livers
from initial oxidative injury at normothermic reperfusion after liver transplantation. This is a unique
feature of a cold oxygenation approach, which is effective also end-ischemically, e.g., after cold
storage, due to mitochondrial repair mechanisms. In contrast, normothermic oxygenated perfusion
concepts protect by reducing cold ischemia, and are therefore most beneficial when applied instead
of cold storage; (3) Due to less downstream activation of cholangiocytes, hypothermic oxygenated
perfusion also significantly reduces the development of biliary strictures after liver transplantation.
Keywords: hypothermic oxygenated perfusion (HOPE); cholangiocyte injury; mitochondria
1. Introduction
The ultimate goal and task for new preservation strategies is to treat and repair high-risk
organs, which were previously deemed not transplantable. With a steadily increasing amount
of data, the transplant community learns that such approaches may enable us to prevent severe
reperfusion injury and subsequent complications after liver transplantation. With the improvement
of anesthesiological and surgical techniques, the majority of transplant recipients achieve an initial
recovery, and the rate of primary-non-function (PNF) is low [1]. However, the major problems in
the field remain the biliary complications after liver transplantation, and accordingly there are two
main strategies physicians put their focus on [2]. The first is to understand which donor-recipient risk
combinations should be avoided and when to say “no” to prevent severe biliary complications [3].
The second is to treat livers before implantation to improve their quality with the use of novel machine
perfusion technology [4]. In order to achieve this goal, an understanding of the underlying mechanism
of biliary injury in the setting of liver transplantation appears mandatory, which is therefore the
first subject of this review. Secondly, we will focus on recent literature including experimental and
clinical studies assessing the impact of machine perfusion technology on the biliary tree and on biliary
complications after liver transplantation.
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2. Overview of Biliary Injury and Underlying Mechanism in the Setting of Liver Transplantation
Anastomotic and non-anastomotic biliary strictures (AS and NAS) are the most common biliary
complications after liver transplantation, with a frequency of 1–15% and 5–30%, respectively [5,6]
(Figure 1). Donation after circulatory death (DCD) livers experience a certain period of warm ischemia
in the donor, which has been recognized in combination with cold storage and other risk factors
as a main cause of the higher incidence of NAS after DCD liver transplantation [7]. In addition,
altered bile acid composition level, triggered by hepatocyte transporter injury and immune-mediated
processes play a cumulative role in the pathogenesis of biliary injury and subsequent formation of
biliary strictures (Figure 1) [8]. Relatively short periods of ischemia already induce a rapid cellular
energy depletion in the very sensitive biliary epithelial cells (cholangiocytes) [9], which subsequently
detach from the basement membrane due to a loss of their intercellular connections. In this context,
several clinical studies have described a significant loss of epithelial cells in large extrahepatic bile
ducts after transplantation of otherwise relatively low-risk livers, donated after brain death (DBD) [10].
Despite the observation that biliary injury is almost universally present (>80%) already before graft
implantation, biliary strictures are seen in only a minority of transplant recipients, which has led to the
hypothesis that the ability of the bile duct wall and epithelium to regenerate is an important feature of
the pathogenesis of biliary strictures. While it is clear that regeneration of the larger bile ducts requires
sufficient oxygen and nutrient supply, this process depends also on the condition of peribiliary glands
in the deeper layers of the bile duct wall, which represent the niche for progenitor cells. Underlining
this theory, newly developed biliary epithelial cells can migrate from the peribiliary glands through
small connecting canals to the bile duct lumen, where they restore the epithelial lining.
The current main explanation for a higher rate of NAS in DCD transplants is therefore an initial
cellular lack of oxygen in hepatocytes and cholangiocytes, leading first to insufficient oxygenation of the
progenitor niche with subsequently impaired regeneration of the larger bile ducts [11]. Secondly, during
reperfusion, mitochondrial-derived oxidative stresses in biliary epithelial cells trigger the release of
reactive oxygen species (ROS) and multiple downstream pathways, including danger signaling,
inflammasome activation, and the release of profibrogenic cytokines, which reinforce cholangiocyte
and hepatocyte injury (Figures 1 and 2). The third cause of biliary injury are immune-mediated
pathways, which depend on blood-type antigens expressed on the biliary epithelia of donor bile
ducts, and lead to an ABO antibody-mediated direct injury of biliary epithelial cells (Figure 1).
Accordingly, ABO-incompatible liver transplantation has been shown to result in higher rates of
NAS [12]. In addition, C-C-Motiv-Chemokin-Receptor 5 ∆ 32 (CCR5-∆ 32) -mutation leads to a higher
incidence of NAS, due to an impaired attraction of regulatory T cells and dysfunction of the immune
defense in the neighborhood of bile ducts [13].
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Figure 1: Type and Etiology of injury of the biliary tree after liver transplantation
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Figure 1. Type and etiology of injury of the biliary tree after liver transplantation. The site and type of
biliary complication are highlighted, and potential causes are described throughout the entire biliary
tree of a liver graft.
Figure	2:	Mechanism	of	cholangiocyte	injury during and after	reperfusion in	the	setting	of	liver	transplantation
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Figure 2. The mechanism of cholangiocyte injury during and after reperfusion in the setting of liver
transplantation. The multifactorial mechanisms of injury are described in this figure. Two main drivers
are responsible for the development of severe biliary complications: First, at reperfusion, oxygen
free radicals are released from the complex of one of the mitochondrial chains in any affected cells,
including hepatocytes and cholangiocytes (1). Secondly, the initial oxidative hit triggers downstream
inflammation (2) and further aggravation with an ultimate chronic inflammatory status (3). Depending
on the liver quality and the amount of graft injury in the donor and during preservation, ATP-dependent
bile acid transporters have already an impaired function, which leads to higher vulnerability against
toxic bile salts. Such a combination of injuries will likewise lead to an impaired ability to facilitate
regeneration of hepatocytes and cholangiocytes (3). BA, Biliary acid; BSEP, Bile salt export pump; MDR,
multidrug resistance.
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Finally, a disturbed bile salt-phospholipid ratio of bile fluid further destroys sensitive biliary
epithelial cells and is caused by insufficient bile salt transporters in hepatocytes, such as Bile salt
export pump (BSEP) and multidrug resistance-3 (MDR 3) [14]. ATP-depletion during warm and
cold ischemia mainly contributes to this alteration in transporter function. An additionally impaired
micelle formation leads to a further decrease of phospholipids in bile, with a subsequent direct bile-salt
mediated injury of cholangiocytes, and an increased rate of NAS [11]. Similarly, a decent HCO3-
(bicarb) concentration in bile is required to protect cholangiocytes from direct penetration by bile
salts and is frequently altered during initial reperfusion [15]. Injured cholangiocytes may also lose
their ability to reabsorb a sufficient amount of bile acids. Such features contribute to an increased
accumulation of toxic bile salts in cholangiocytes with subsequent cholangiocyte and hepatocyte injury,
mainly in larger bile ducts (Figures 1 and 2).
3. Risk Factors for Development of Biliary Complications after Liver Transplantation
Before the era of cold storage, ex-situ perfusion of organs had already received particular interest
with the aim to maintain organ function outside of the human body by continuously supplying oxygen
and nutrients. Yet, with the advent of modern preservation solutions, simple cooling became very
attractive and efficient for keeping an organ transplantable for several hours, without severe loss of
viability. Accordingly, cold storage remains also nowadays an easy and very successful preservation
technique for normal or ideal liver grafts, actually confirmed by a recent benchmark study of cold
stored “ideal” primary liver transplants [16]. However, for non-ideal, or so-called marginal liver grafts,
the limits of static preservations and techniques have been widely recognized, and machine perfusion
techniques have recently been acknowledged for their potential advantages in optimizing organ
functions in these grafts. It is notable that definitions of such extended criteria donor livers (ECD) are
somewhat arbitrary and include, for example, an advanced donor age of 60–80 years, hepatic steatosis
of 15–30 %, and prolonged cold storage of more than 10–12 h [16–21]. Importantly, most European
centers routinely face liver offers from donors above 60 years of age, together with a significant amount
of steatosis in the era of non-alcoholic steatohepatitis (NASH) [22,23], implicating that the “normal”
liver graft today is often already aged between 60 and 70 years, with significant macrosteatosis up
to 15%, and cold ischemia up to 10 h. Of note, such data differs from the US data, underlined by a
significantly lower donor risk index (DRI) [24].
The extended criteria in Europe includes currently liver grafts with high amounts of macrosteatosis
(>30 or >40 % (EASL guidelines), prolonged cold ischemia (>12 h), additional donor warm ischemia
(DCD), or a very high donor age (>80 years) (EASL guidelines) [25]. Those liver grafts will likewise
need optimization before implantation, especially when combined with risky recipients (including
retransplantation and high model of end-stage liver disease—MELD score patients) [26].
4. General Strategies of Biliary Tree Protection
The general concepts used to improve outcomes in liver transplantations mainly include technical
factors, e.g., quick retrievals with short hepatectomy times (below 40 min) [27,28] and extensive bile
duct flushes in-situ and ex-situ [27] to remove toxic bile acids [29]. Since well-known risk factors,
including donor age [30], donor Body-Mass-Index (BMI) and amount of steatosis [30], and the duration
of donor warm ischemia (asystolic warm ischemia < 10 min) [31] are unchangeable, careful selection is
the only remaining option to reduce the overall risk. Several transplant programs tend therefore to
limit, for example, their cold ischemia to 6 h for DCD and fatty livers [3], and aim to reduce the period
between portal vein and arterial anastomosis to supply enough oxygen to the biliary tree as quickly
as possible after normothermic reperfusion. It is unclear whether simultaneous portal and arterial
reperfusion provides real benefit in terms of biliary injury. In addition, a reduced portal clamping
time, by application of a portocaval shunt may protect from bacterial translocation and subsequent
LPS-induced aggravation of reperfusion injury [31,32].
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5. Machine Perfusion
In addition to a reduction of cold and warm ischemia times, ex-situ graft treatment by dynamic
preservation techniques appears as a further option to achieve repair of pre-injured liver grafts before
implantation. For the livers, two main perfusion approaches are tested in the clinic; either perfusion
with blood at physiologic, normothermic or sub-normothermic conditions or perfusion with cooled
oxygenated artificial fluids. Normothermic machine perfusion (NMP) aims to replace the cold storage
and is applied either in-situ, in donors before procurement (normothermic regional perfusion—NRP),
or ex-situ during organ transport [33–36]. Consecutively, the first randomized controlled NMP trial on
livers predominantly donated after brain death (DBD) showed an excellent 1-year patient- and graft-
survival rate of 97% [37]. The rates of biliary complications were however not significantly different
between the normothermic and cold storage groups and appeared high in both study arms for DCD
livers (NAS: 11 vs. 26%, AS: 48 vs. 58%) (Tables 1 and 2) [37]. Despite the advantages to solving
logistical issues, the effects of normothermic machine perfusion (and more specifically normothermic
perfusion after cold storage) became less obvious when the cold storage duration of the matched
control group was further reduced [38].
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Table 1. Experimental studies analyzing the impact of machine perfusion on the biliary tree between 2013–2018.
Author Year Model Species Temp (◦C) PerfusionDuration (h)
Perfusion
Route OLT Endpoints Outcome
Goldaracena
et al. [39] 2016 DBD Pig 33, 37 4 PV + HA Yes
Ischemia-Reperfusion
Injury, bile duct injury, liver
function (3 day follow up)
Addition of anti-inflammatory
substances during sub-and
normothermic perfusion improve all
endpoints and may reduce biliary injury
Spetzler et al.
[40] 2016 DBD Pig 33 4 PV + HA Yes
Ischemia-Reperfusion
Injury, bile duct injury,
liver function, histology
Subnormothermic perfusion improves
outcomes after transplantation
Fontes et al. [41] 2015 Pig 21 PV + HA Yes
Liver function and injury,
markers for biliary injury,
inflammation and animal
survival
Subnormothermic perfusion improves
liver function, bile procudetion and
survival and reduces the inflammation
after liver transplantation,
documentation of mediator release
(regenerative pathways and
inflammation) during subnormothermic
perfusion
Knaak et al. [42] 2014 DCD Pig 33 3 PV + HA Yes
Endothelial and biliary
injury and liver function,
animal survival
Endischemic subnormothermic
perfusion reduces biliary and
endothelial cell injury after
transplantation
Schlegel et al.
[43] 2013 DCD Rat 4 1 PV Yes
Ischemia-Reperfusion
Injury, graft function,
animal survival, biliary
parameters and histology
4 weeks after OLT
HOPE treated DCD livers showed
significantly less biliary cirrhosis and
fibrosis within 4 weeks after liver
transplantation. Such reduced injury is
mediated through less reperfusion
injury after HOPE treatment
Banan et al. [44] 2016 DBD Pig
38, gradual
rewarming + 38 4–8 PV + HA No
Markers of hepatocyte
injury and biliary tree
injury
Reduced biliary epithelial cell injury in
gradually rewarmed grafts (rewarming
+ normotherm better preservation of
biliary tree compared to direct
normotherm perfusion)
Op den Dries
et al. [35] 2016 DBD + DCD Rat 37 3 PV + HA No
Markers of biliary function
and injury, histology
Normothermic perfusion protects bile
ducts when performed instead of cold
storage
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Table 1. Cont.
Author Year Model Species Temp (◦C) PerfusionDuration (h)
Perfusion
Route OLT Endpoints Outcome
Westerkamp
et al. [45] 2015 DCD Rat 10, 20, COR 2 PV + HA No
Markers of biliary function
and injury, histology
Less injury of large bile duct epithelium
compared to cold storage alone
Liu et al. [36] 2014 DCD Pig 38 10 PV + HA No
Markers of biliary function
and injury, histology
Normothermic perfusion instead of cold
storage improves regeneration of biliary
epithelial cells
Op den Dries
et al. [46] 2014 DBD + DCD Pig 10 4 PV + HA No
Markers of biliary function
and injury, histology
Hypothermic perfusion prevents
ateriolonecrosis of the peribiliary
vascular plexus of the bile ducts
HOPE: Hypothermic oxygenated perfusion; DBD: Donation after brain death; DCD: Donation after circulatory death; PV: Portal vein; HA: Hepatic artery; COR: Controlled oxygenated
rewarming, OLT: Orthotopic Liver Transplantation.
Table 2. Impact of machine perfusion on biliary complications after liver transplantation (clinical studies, 2015–2018).
Author Year Model n Technique Temp(◦C) Device
Perfusion
Duration (h)
Perfusion
Route Endpoints Outcome
Watson et al.
[47] 2018 DCD 44 NRP 37 Maquet/ECOPS 2 NRP
Peak ALT, graft function,
biliary complications, 90-day
survival
NRP is a successful selection tool,
DCD livers recovered with NRP
showed significant less biliary
complications (AS and NAS), no
differences in graft survival
Hessheimer
et al. [48] 2018 DCD 97 NRP 37 ECMO 2 NRP
graft function, biliary
complications, 1-year graft
survival
NRP is a successful selection tool,
DCD livers recovered with NRP
showed significant less biliary
complications (AS and NAS), no
significant differences in graft survival
Nasralla
et al. K [37] 2018 DBD + DCD 121 (34 DCD) NMP 37 Organox metra 9.1 PV + HA
AST release and 1-year
survival after liver
transplantation
No difference in biliary complications
(AS, NAS), reduced AST release after
reperfusion
Watson et al.
[49] 2018 DBD + DCD 22 (16 DCD) NMP 37 Liver Assist 4–6 PV + HA
Post-Reperfusion syndrome,
graft function, rate of PNF,
biliary complication, bile duct
histology and graft survival
25% of transplanted DCD livers
developed a NAS, Bile pH during
NMP is currently the best predictor for
biliary complications at the cutoff 7.5
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Table 2. Cont.
Author Year Model n Technique Temp(◦C) Device
Perfusion
Duration (h)
Perfusion
Route Endpoints Outcome
Bral et al. ﬂ
[38] 2017 DBD + DCD 9 (4 DCD) NMP 37 Organox Metra 11.5 PV + HA
Graft function and injury,
biliary complications, graft
survival
Longer ITU and hospital stay in NMP
group
Schlegel
et al. [50] 2018 DCD 50 HOPE 10 Liver Assist 2 PV
Post-Reperfusion syndrome,
graft function, rate of PNF,
HAT and ischemic
cholangiopathy, 5-year graft
survival
HOPE treated extended DCD liver
grafts showed significant improved
5-year graft survival due to less PNF,
HAT and ischemic cholangiopathy
De Carlis
et al. [51] 2018 DCD (II, III) 15
ECMO +
HOPE 37, 10
ECMO/Liver
Assist 2, 2
ECMO, PV
+ HA
Liver function, biliary
complications, 1-year survival
No significant differences in biliary
complications compared to DBD
matching group, 2 NAS
(endoscopically treated), no significant
differences in survival
Van Rijn
et al. [52] 2018 DCD 20 DHOPE 10 Liver Assist 2 PV + HA
Markers of biliary injury
including histology of bile
ducts
D-HOPE treatment restored hepatic
ATP and protects the biliary tree from
reperfusion injury and complications
Van Rijn
et al. [53] 2017 DCD 10 DHOPE 10 Liver Assist 2 PV + HA
Liver function, ATP content,
biliary complications, graft-
and patient survival
D-HOPE treatment protect from
reperfusion injury and improved 6 and
12 month graft survival and reduced
biliary complications
Dutkowski
et al. [54] 2015 DCD 25 HOPE 10 Liver Assist 1–2 PV
Graft function, EAD, biliary
complications, graft and
patient survival
HOPE treated extended DCD liver
grafts showed comparable outcomes
to matched low-risk primary DBD
transplants, biliary complications were
reduced compared to untreated DCD
liver transplants
Guarrera
et al. [55] 2015
ECD (no
DCD) 20 HMP 4-8 Medtronic 4–7 PV + HA
Incidence of PNF, EAD,
vascular and biliary
complication, 1-year graft and
patient survival
HMP showed significantly less biliary
complications
All studies above are transplant studies, reporting the impact of the perfusion approach on biliary complications as primary or secondary endpoints; n represents the perfused livers or
donors, where studies with at least 9–10 perfusions were included; HMP: Hypothermic machine perfusion; HOPE: Hypothermic oxygenated perfusion; DHOPE: Dual-HOPE; ECD:
Extended criteria donors; DBD: Donation after brain death; DCD: Donation after circulatory death; PV: Portal vein; HA: Hepatic artery; EAD: Early allograft dysfunction; PNF: Primary
non function; HAT: Hepatic artery thrombosis; Perfusion device: J. Guarrera, applied his HMP through a non-pulsatile pump (Medtronic, Minneapolis, MN, USA); AS: Anastomotic
strictures; NAS: Non-anastomotic strictures; DCD (II, III): Maastricht II and III category DCD (Italy), 20 min stand off period in donor; NRP: Normothermic regional perfusion in donor;
NMP: Normothermic Machine perfusion; AST: Aspartate-Aminotransferase;K: Randomized controlled trial, powered for AST release as primary endpoint; Reference [35] includes the
first 20 livers of this randomized controlled trial; ﬂ: NMP livers were matched to cold storage livers, where the control group was of low risk with short cold ischemia time; ECMO:
Extracorporeal membrane oxygenation; ALT: Alanine-Aminotransferase .
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Upfront normothermic perfusion already in the donor (NRP) is currently performed in Maastricht
III DCD donors in Spain and in the UK with low rates of cholangiopathies [47,48]. One limitation of
this approach is the fact that grafts which perform poorly during NRP are discarded, which amounts
currently to a rate of approximately 40% non-usable grafts by NRP techniques [56].
In contrast to an upfront (NRP) or continuous normothermic machine perfusion (NMP) during
the entire preservation period, hypothermic oxygenated perfusion (HOPE) is applied end-ischemically
after cold storage [26,45,54]. Recent observational studies reported 5-year tumor death-censored
patient survival above 95% in extended Maastricht III DCD livers (donated after cardiac death) treated
by HOPE [50], comparable to DBD livers. Of note, endischemic HOPE resulted in no graft loss by
ischemic cholangiopathy, despite application in high-risk grafts and despite a utilization rate of 90%
(Tables 1 and 2, Figure 3) [50]. HOPE treatment has also been applied recently in Maastricht Type II
DCD livers, following initial NRP [51]. Such clinical results in humans were paralleled by experimental
studies in livers [43,46] and also in kidneys [57].Figure	3:	Hypothermic	oxygenated	perfusion	(HOPE)	in	human	and rat	DCD	livers
Example	of	human	DCD	 liver	during	HOPE	 treatment Human	and	rat	DCD	 livers	during	and	after	HOPE	perfusion	with	FluoresceineA B
A:	Extended	 Human	DCD	liver	graft	during	hypothermic	 oxygenated	
perfusion	 (HOPE)
B:	Human	and	rat	DCD	liver	grafts	during	and	after	hypothermic	
oxygenated	perfusion	 with	Fluoresceine.	
Both,	 human	and	rat	liver	biliary	trees	are	stained	with	Fluoresceine,	
despite	portal	 vein	perfusion	 only,	through	 small	connecting	 venous	
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1&2:	human	liver	homogenously	stained	with	Fluoresceine after	HOPE.	
3:	Distal	part	of	human	liver	common	bile	duct	 (suture	marked),	
completely	stained	with	 Fluoresceine during	 HOPE-treatment
4&5:	Rat	liver	homogenously	stained	with	Fluoresceine after	HOPE.	
6&7:	Distal	part	of	rat	liver	common	 bile	duct,	 completely	stained	with	
Fluoresceine during	HOPE-treatment	 (2	different	 rat	liver	grafts)
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Figure 3. Hypothermic oxygenated perfusion (HOPE) in human and rat DCD livers. (A) An example
of hypothermic oxygenated perfusion (HOPE) of an extended DCD liver graft prior to transplantation.
(B) To confirm a complete perfusion with highly-oxygenated perfusate in the cold during HOPE,
Fluorescein was added to the perfusate. Both human and rat livers showed a rapid complete perfusion
in the cold, despite a low perfusion pressure of 3 mmHg or less. Notably, the entire biliary tree,
including the distal tip where the anastomosis is performed with the recipient bile duct, appears also
completely stained, which confirms that the perfusate and more importantly the oxygen has reached
all liver cells including cholangiocytes. The approval numbers were KEK ZH 2012-1 (January 2012)
and KEK ZH 2017-00309 (July 2017), both approved by the Cantonal Ethic Commission in Zurich.
Importantly, while the original HOPE treatment is applied only through the portal vein, the group
from Groningen currently favors dual hypothermic oxygenated perfusion through the portal vein
and the hepatic artery (D-HOPE) [52], and reported the first 20 extended DCD liver grafts with no
graft loss in the D-HOPE group compared to un-perfused controls (Table 2) [53]. Randomized trials
have been initiated to further evaluate the effect of HOPE and D-HOPE in DBD and DCD liver grafts
(Hope-liver.com—Zurich, Groningen Institute for Organ transplantation (GIOT)). Another perfusion
approach currently being explored is subnormothermic perfusion, either instead of cold storage or
endischemically, and experimental studies have shown promising results in terms of reduction of
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reperfusion injury and later liver and bile duct histology with subsequently less biliary complications
in preclinical studies [39–42].
Notably, randomized trials comparing concurrent dynamic preservation techniques (NRP vs.
normothermic vs. hypothermic) have yet not been performed in any kind of solid organs, and the
exact mechanism of protection for each technique remains controversial.
6. Suggested Decisive Mechanisms of Machine Liver Perfusion Techniques Against Biliary
Injury
Recent research points to three targets for dynamic preservation technology in order to achieve
fewer biliary complications after liver transplantation. First, accumulated citric acid metabolites,
e.g., mainly succinate, during ischemia have been shown to trigger mitochondrial dysfunction in
various tissues including livers, lungs, kidney, brain, and heart [58,59]. Active breakdown of these
metabolites before reperfusion would therefore be of major importance to guarantee a well-functioning
mitochondrial electron transport during early normothermic reperfusion. A currently unique approach
to achieve this task is the introduction of oxygen to the ischemic tissue at cold instead of warm
temperature, which results in metabolization of succinate without a concomitant release of reactive
oxygen species [60]. Mitochondria are therefore primed by a relatively short phase of hypothermic
oxygenated perfusion (HOPE) to function better upon reperfusion under normothermic conditions
(Figure 3) [60]. Secondly, cellular energy stores are depleted during any kind of ischemia and need to be
uploaded before implantation. Among the major ATP-consuming processes are bile salt transporters,
ion channel pumps, and cellular mitotic activities [43]. The regenerative capacity of tissues, including
the peribiliary glands, depends therefore on the presence of sufficient levels of phosphorylated
nucleotides. Normothermic oxygenated perfusion has been shown to restore liver ATP levels as
compared to cold storage (Figure 2) [44,61]. Remarkably though, hypothermic oxygenated perfusion
achieves an even higher rate of energy tissue recharging due to a higher ATP yield per oxygen molecule
below the Arrhenius breakpoint temperature of 15 ◦C [61–63].
Third, the consequences of normal-functioning mitochondria and uploaded ATP and ADP
levels in the first minutes of ischemia reperfusion are multifactorial. These include the prevention
of mitochondrial ROS release from complex I during implantation in all liver cells, including
cholangiocytes and hepatocytes, and prevention of down-stream inflammasome activation during
implantation (Figure 2) [60,64]. It remains unclear whether additional perfusion effects are equally
important, such as improvement of arterial microvascular flow by perfusion approaches [46],
nutritional support of cholangiocytes [35], and removal of accumulated toxic substances [11,55].
7. Prediction of Biliary Complications in Liver Transplantation
A low bile pH (<7.4) during normothermic machine perfusion before implantation serves currently
as the best predictor for later ischemic biliary complications (Table 2) [49]. This parallels earlier results
from the group of Robert Porte, who suggested to measure bicarbonate in the bile as a surrogate
marker of cholangiocyte function [65]. In contrast, lactate clearance, liver enzyme release, and bile
production during normothermic machine perfusion were only weak predictors for both graft function
and biliary complications [49,66]. Bile pH analysis appears also not reliable during hypothermic
perfusion due to insufficient bile production in the cold. Quantification of microRNA from cold
flushes or perfusates has been somehow predictive for later biliary complications, but needs further
validation [67]. Metabolomic and glyconomics assessments of the cold flush solution and liver biopsies
before implantation have been published, but focus solely on the occurrence of primary non-function
or early allograft dysfunction [68,69].
8. Conclusions and Future Perspective
Machine perfusion technology has a great potential to modify multiple cellular metabolic reactions
prior to liver implantation, with significant impact on inflammation and also immune response
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pathways [60]. In terms of the suggested mechanistic view above, it would be of major importance to
determine mitochondrial viability in cells during any machine perfusion approach, instead of analysis
of surrogate markers in perfusate or bile. This would clarify whether the perfused liver has already
been fully recharged and safely reconditioned to prevent major DAMP signaling and down-stream
inflammasome activation during implantation [61,64]. We anticipate, therefore, that in the next few
years a better understanding should be available, enabling a perfusion strategy which should be
applied in accordance with the type and injury of each liver in order to prevent biliary injury.
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CCR5-∆ 32 C-C-Motiv-Chemokin-Receptor 5 ∆ 32
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DBD Donation after brain death
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MPT pore Mitochondria permeability transition pore
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